Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ T lymphocytes and impair cell-mediated immunity, increasing risk of certain infections and cancers.
The COVID-19 pandemic has highlighted the urgency for regional health security, spurring an unprecedented drive since 2020 to establish a robust vaccine production capability within Africa.